Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Market Closed - Nyse Other stock markets 01:30:02 30/04/2024 am IST			5-day change	1st Jan Change
161.5 ^USD	+1.19%		-3.79%	+4.23%

05:26pm	BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	MT
02:52pm	Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	08:56pm	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	06:22pm	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	06:01pm	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	19/04	MT
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	27/03	MT
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	23/03	MT
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing	21/03	MT
ANALYST RECOMMENDATIONS : Abbvie, Align Technology; Ulta Beauty, United Airlines, Currys...	15/03
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	26/02
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	15/02	MT
UBS Adjusts Price Target on AbbVie to $172 from $165, Maintains Neutral Rating	06/02	MT
Truist Adjusts Price Target on AbbVie to $195 From $180, Maintains Buy Rating	06/02	MT
Piper Sandler Adjusts Price Target on AbbVie to $185 From $180, Maintains Overweight Rating	05/02	MT
Morningstar Upgrades AbbVie to Hold From Sell, Increases Price Target to $168 From $137	05/02	MT
Wells Fargo Adjusts Price Target on AbbVie to $200 From $180, Maintains Overweight Rating	05/02	MT
Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating	05/02	MT
BMO Capital Adjusts Price Target on AbbVie to $195 From $187, Maintains Outperform Rating	05/02	MT
Barclays Adjusts Price Target on AbbVie to $185 From $175, Maintains Overweight Rating	05/02	MT
Raymond James Adjusts Price Target on AbbVie to $189 From $181, Maintains Outperform Rating	05/02	MT
Powell, the paper tiger	05/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Analyst Reco.

Filters